OncoZero AI Clinches $1M Funding to Accelerate Revolutionary Liver Cancer Diagnosis Technology

OncoZero.AI is proud to announce its latest funding milestone, having raised $1,000,000 to further advance its mission in revolutionizing oncological diagnostics. As an innovative medical technology company, OncoZero.AI is developing a comprehensive online ecosystem dedicated to the early and accurate diagnosis of cancer, with an initial focus on liver cancer—a condition known for its complexity and critical need for timely treatment. This investment will propel the development of their inaugural product, designed specifically for the detection and diagnosis of liver cancer by leveraging cutting-edge imaging technology and data analysis. At the core of their breakthrough approach is the QAM metric, a proprietary system that utilizes volumetric segmentations of tumors and ablation zones along with maps of signed Euclidean distances to accurately assess tumor boundaries. This unique methodology not only enhances diagnostic precision but also holds significant potential in guiding targeted treatment strategies, aiming to improve patient outcomes dramatically. The remarkable success of this funding round underscores the confidence investors have in OncoZero.AI’s vision and the expertise of its dynamic team, which boasts accolades such as winners of the Republican Mathematics Olympiad, three-time champions of the World Robotics Olympiad, and talent drawn from leading financial institutions like Jusan Bank and Altyn Bank. Additionally, the company benefits from robust collaborations with prestigious institutions including the University Medical Center Astana, Warwick University, and Astana IT University. With this crucial capital infusion, OncoZero.AI is well positioned to scale its operations and bring transformative innovations to the field of oncology, ultimately paving the way for improved diagnostic capabilities and enhanced care for liver cancer patients worldwide.